Business
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright.
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, was discussed by field-leading key opinion leaders (KOLs) during a recent event hosted by H.C. Wainwright.","length":308,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.)","displaySize":"","headline":null,"caption":"Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":174,"url":"https://media.zenfs.com/en/prnewswire.com/caf9efe53f239ce497937f5fab3fe90d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dOUtzp14m4TWUZEBzfpHDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMwNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/caf9efe53f239ce497937f5fab3fe90d","width":400,"height":174}},"href":"https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"Martine Piccart, M.D., Ph.D., an Honorary Professor of Oncology at the Université Libre de Bruxelles (ULB) and Scientific Director of Oncology at the Institut Jules Bordet, in Brussels, Belgium, offered a detailed overview of the HR+/HER2- metastatic breast cancer landscape and emphasized the need for new treatment innovations, such as pelareorep, that work to activate the immune system to recognize and kill cancer.","length":419,"tagName":"p"},{"type":"text","content":"Alexander Eggermont, M.D., Ph.D., Professor of Clinical & Translational Immunotherapy at the University Medical Center Utrecht in the Netherlands and Board Member of the Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximilians University, Munich, Germany, provided insights on the current standards for treating pancreatic ductal adenocarcinoma (PDAC), a cancer type known for its resistance to treatment, and the potential impacts that an immunotherapy such as pelareorep might have on the field.","length":541,"tagName":"p"},{"type":"text","content":"A replay of the full conversation can be found by clicking here.","length":64...